Highlights Gastric cancer is a common gastrointestinal malignant tumor, accounting for the fourth place in the global incidence of malignant tumors, and the third place in cancer mortality. Although chemotherapy is the main treatment for patients with advanced gastric cancer, adverse reactions are more prominent. With the deepening of scientific research, there are more and more targeted therapies for gastric cancer. The author introduces the relevant targets and targeted drugs for targeted treatment of advanced gastric cancer, hoping to provide a reference for clinically targeted treatment of advanced gastric cancer. Abstract The incidence of gastric cancer ranks 4th in malignant tumors, and the mortality rate ranks 3rd in malignant tumors. Most patients with gastric cancer are already at the advanced stage when diagnosed. Although chemotherapy is the main treatment for patients with advanced gastric cancer, it can extend the overall survival. But adverse reactions are more prominent. With the rise of targeted therapy, the molecular mechanism of gastric cancer occurrence and development continues to develop, and molecular targeted therapy of gastric cancer has gradually emerged. The current targets for gastric cancer mainly include endothelial growth factor receptor, HER2, vascular endothelium growth factor, vascular endothelium growth factor receptor, mammalian rapamycin receptor, hepatocellular growth factor, et al., but the clinical efficacy is still not satisfactory. At present, most of the studies on molecular targeted drugs for gastric cancer have ended in failure. The heterogeneity between patients and the prognosis of tumors in different parts may be different. It is suggested that screening targeted drugs according to the patient's pathological characteristics and molecular typing, and individualized treatment is the inevitable way of targeted treatment of gastric cancer.
展开▼
